28 completed, 6 unknown, 4 withdrawn, 2 recruiting. 12 Phase 2, 10 Phase 3, 8 Not applicable, 7 Phase 1, 5 Phase 4.
Follow Hydralazine: new trials by email Literature Review of Hydralazine trials Research Report on Hydralazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Intravenous Labetalol and Intravenous Hydralazine in Severe Preeclampsia Labetalol, Hydralazine - Preeclampsia | Not applicable | Completed | Muhammad Aamir Latif | 132 | 2024-05-01 | 2026-05-07 |
| Intravenous Labetalol Versus Hydralazine in Preeclampsia Labetalol Injection, HydrALAZINE Injection - Preeclampsia Severe | Phase 1 / Phase 2 | Unknown | Tanta University | 40 | 2024-04-01 | 2024-12-02 |
| Effect of Hydralazine on Alzheimer's Disease Hydralazine hydrochloride 25mg tablets, Placebo - Alzheimer Disease | Phase 3 | Completed | Shahid Sadoughi University of Medical Sciences and Health Services | 228 | 2021-08-02 | 2026-09-09 |
| Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts Furosemide, Torsemide, Bumetanide - Heart Failure, Congestive | Phase 4 | Recruiting | Heart Center Research, LLC | 80 | 2021-07-08 | 2024-01-29 |
| Blood Pressure Management in Stroke Following Endovascular Treatment Labetalol, Hydralazine, Enalapril - Stroke, Acute, Vessels; Occlusion | Phase 2 | Completed | Hamilton Health Sciences Corporation | 30 | 2020-10-23 | 2023-11-07 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 | |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Blood Pressure After Endovascular Stroke Therapy-II Nicardipine, Labetalol, Hydralazine - Acute Stroke, Endovascular Thrombectomy | Phase 2 | Completed | University of Cincinnati | 120 | 2020-01-17 | 2023-10-12 |
| Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence and Etiologic Factors Types of Anesthesia, Access of Surgery, Comorbidities - Delirium, Anesthesia; Adverse Effect | Completed | Sultan Qaboos University | 402 | 2019-01-01 | 2019-05-30 | |
| Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in Pregnancy Hydralazine, Nifedipine - Hypertension | Not applicable | Completed | Adebayo Joshua Adeniyi | 69 | 2018-08-13 | 2020-06-17 |
| Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients Hydralazine - Polycystic Kidney Diseases | Early Phase 1 | Completed | University of Kansas Medical Center | 14 | 2018-04-23 | 2020-02-26 |
| Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD Hydralazine/Isorsorbide Dinitrate, Placebo - Chronic Hemodialysis (ESRD) | Phase 4 | Completed | Brigham and Women's Hospital | 17 | 2017-08-28 | 2021-04-27 |
| The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation evidence-based medications vs. high-dose hydralazine + evidence-based medications - Systolic Heart Failure Stage D (Disorder), Mitral Regurgitation | Phase 4 | Unknown | Kaohsiung Veterans General Hospital. | 400 | 2017-01-01 | 2022-01-06 |
| Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols Labetalol, Hydralazine, nifedipine - Hypertension | Not applicable | Withdrawn | St. Louis University | 2016-08-01 | 2017-11-13 | |
| Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets BiDil XR, BiDil Immediate Release (IR) - Heart Failure | Phase 1 | Completed | Arbor Pharmaceuticals, Inc. | 12 | 2015-09-01 | 2016-11-08 |
| Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer Hydralazine/Magnesium, Placebo, Carboplatin - Cervical Cancer | Phase 3 | Withdrawn | National Institute of Cancerología | 2015-01-01 | 2025-05-29 | |
| Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study Hydralazine, Isosorbide Dinitrate - Cardio-Renal Syndrome | Phase 3 | Unknown | National University Hospital, Singapore | 100 | 2015-01-01 | 2015-01-22 |
| Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure Hydralazine, Isosorbide Dinitrate - Acute Heart Failure, Left Ventricular Dysfunction | Phase 3 | Unknown | University of Cape Town | 500 | 2013-01-01 | 2015-08-14 |
| Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients. Labetalol, Hydralazine - Hypertension, Pregnancy Induced, Hydralazine Adverse Reaction | Phase 2 | Completed | Dow University of Health Sciences | 190 | 2012-10-01 | 2018-10-26 |
| Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy Hydralazine, Labetalol - Hypertension, Pregnancy Induced | Phase 3 | Completed | Saint Thomas Hospital, Panama | 261 | 2012-07-01 | 2013-05-17 |
Showing 20 of 42. Sign in to see all of them.
Hypertension (13) · Heart Failure (5) · Stroke (4) · Cardiovascular Diseases (3) · Uterine Cervical Neoplasms (3) · Cerebral Hemorrhage (2) · Diabetes Mellitus, Type 2 (2) · Hypertension, Pregnancy-Induced (2) · Intracranial Hemorrhages (2) · Pre-Eclampsia (2) · Adrenal Insufficiency (1) · Alzheimer Disease (1) · Anosmia (1) · Arrhythmias, Cardiac (1) · Atherosclerosis (1)
National Institute of Cancerología (6) · The George Institute (3) · Arbor Pharmaceuticals, Inc. (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · University of Arkansas (2) · Adebayo Joshua Adeniyi (1) · Brigham and Women's Hospital (1) · Corporal Michael J. Crescenz VA Medical Center (1) · Creighton University (1) · Dow University of Health Sciences (1) · Duke University (1) · Hamilton Health Sciences Corporation (1) · Heart Center Research, LLC (1) · Kaohsiung Veterans General Hospital. (1) · Muhammad Aamir Latif (1)
United States (17) · Mexico (6) · Australia (3) · Canada (3) · Pakistan (3) · Brazil (2) · China (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Chile (1) · Egypt (1) · Finland (1) · France (1)
Ahmed M Safar, MD (2) · Craig Anderson, PhD (2) · Adam P Bress, PharmD, MS (1) · Alfonso Duenas-Gonzalez, MD PhD (1) · Alfonso Duenas-Gonzalez, MD, PhD. (1) · Aristeidis H Katsanos, MD (1) · Bruce Neal, PhD (1) · Cetina Lucely, MSc (1) · Chi Hornik (1) · Claudia Arce, MD (1) · Craig S Anderson, MD (1) · David Charytan, MD (1) · David J Webb, MD (1) · Denise Simons-Morton, MD, PhD (1)
PMID 32640944, PMID 25503550, PMID 25589782, PMID 25657175, PMID 25712944, PMID 25823544, PMID 26746184, PMID 27165954, PMID 27178897, PMID 27919055, PMID 30890109, PMID 31085948, PMID 33598552, PMID 38018833, PMID 40541207, PMID 41855454, PMID 42848972, PMID 10851208, PMID 11927799, PMID 12119802, PMID 12923400, PMID 15738343, PMID 16391172, PMID 16533484, PMID 17183730, PMID 17761710, PMID 18396107, PMID 18426998, PMID 18539917, PMID 19047577, PMID 19738158, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 20823381, PMID 21366473, PMID 21663644, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22129475, PMID 22179956, PMID 22374637
K23NS113858 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), R21AG043802 (1), UL1TR002366 (1)